Weybosset Research & Management’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
Sell
-40,442
Closed -$3.37M 57
2018
Q4
$3.37M Sell
40,442
-527
-1% -$49.4K 2.3% 20
2018
Q3
$4.42M Buy
40,969
+850
+2% +$93.2K 2.55% 20
2018
Q2
$4.41M Sell
40,119
-270
-0.7% -$28.1K 2.67% 20
2018
Q1
$4.05M Buy
40,389
+2,897
+8% +$297K 2.43% 21
2017
Q4
$3.69M Buy
37,492
+215
+0.6% +$20.4K 2.25% 21
2017
Q3
$3.49M Sell
37,277
-1,443
-4% -$153K 2.32% 20
2017
Q2
$4.3M Sell
38,720
-445
-1% -$47.1K 2.77% 18
2017
Q1
$3.85M Buy
39,165
+560
+1% +$53.4K 2.6% 18
2016
Q4
$3.55M Buy
38,605
+155
+0.4% +$13.4K 2.49% 18
2016
Q3
$3.25M Sell
38,450
-57
-0.1% -$4.79K 2.36% 20
2016
Q2
$3.13M Buy
38,507
+2,771
+8% +$211K 2.39% 19
2016
Q1
$2.55M Buy
35,736
+359
+1% +$24.1K 2.16% 22
2015
Q4
$2.52M Sell
35,377
-6,514
-16% -$438K 2.23% 20
2015
Q3
$2.58M Sell
41,891
-531
-1% -$37.1K 1.92% 21
2015
Q2
$3.08M Sell
42,422
-955
-2% -$70.5K 2.03% 20
2015
Q1
$3.33M Buy
+43,377
New +$3.11M 2.11% 20

Other funds holding DGX

Weybosset Research & Management's DGX Position: Q1 2019 in Review

Weybosset Research & Management sold out of Quest Diagnostics (DGX) in Q1 2019, closing a stake of 40,442 shares — an estimated $3.37M sold.

Weybosset Research & Management first reported a position in DGX in Q1 2015 and held it in 16 quarters. The position peaked at $4.42M in Q3 2018. 656 funds tracked by Wall St. Rank hold DGX as of Q1 2019.

  • Weybosset Research & Management reported no remaining Quest Diagnostics position as of Q1 2019 after selling out during the quarter.
  • Weybosset Research & Management sold 40,442 Quest Diagnostics shares in Q1 2019, an estimated $3.37M.
  • Weybosset Research & Management first reported a position in Quest Diagnostics in Q1 2015 and held it in 16 quarters.
  • Weybosset Research & Management's Quest Diagnostics position peaked at $4.42M in Q3 2018.
  • 656 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2019.

Based on Weybosset Research & Management's 13F filing for Q1 2019, filed 15 Apr 2019.